Demonstrating that this co-regulatory mechanism is relevant in a prostate cancer setting required a prostate cancer cell line with stable knockdown of FKBP52 protein in which to assess β-catenin effects on AR activity in the presence or absence of significant levels of FKBP52. The gene discussed is FKBP4; the disease is Familial prostate cancer.